US20100113385A1 - Complex combining an organic silicon derivative with hyaluronic acid calibrated fragments, for preventive and repairing action of cutaneous damages - Google Patents

Complex combining an organic silicon derivative with hyaluronic acid calibrated fragments, for preventive and repairing action of cutaneous damages Download PDF

Info

Publication number
US20100113385A1
US20100113385A1 US12/572,658 US57265809A US2010113385A1 US 20100113385 A1 US20100113385 A1 US 20100113385A1 US 57265809 A US57265809 A US 57265809A US 2010113385 A1 US2010113385 A1 US 2010113385A1
Authority
US
United States
Prior art keywords
fragments
kda
complex
molecular weight
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/572,658
Inventor
Marie-Christine Seguin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exsymol SAM
EXZYMOL M SA
Original Assignee
EXZYMOL M SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EXZYMOL M SA filed Critical EXZYMOL M SA
Publication of US20100113385A1 publication Critical patent/US20100113385A1/en
Assigned to EXSYMOL S.A.M. reassignment EXSYMOL S.A.M. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SEGUIN, MARIE CHRISTINE
Priority to US13/649,640 priority Critical patent/US8822433B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A61K8/585Organosilicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0834Compounds having one or more O-Si linkage
    • C07F7/0836Compounds with one or more Si-OH or Si-O-metal linkage
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Definitions

  • the invention concerns a complex combining an organic silicon derivative with one or several hyaluronic acid calibrated fragments, and its use in the prevention or the repair of cutaneous damages.
  • hyaluronane Linear polysaccharide constituted of repetitive units of D-glucuronic acid and N-acetyl-D-glucosamine, the hyaluronic acid is found in the extra-cellular matrix of numerous connective tissues (skin, tendons, muscles, etc), more precisely as a polyanion called “hyaluronane”.
  • HA hyaluronic acid
  • the HA synthesized by fibroblasts and keratinocytes (hereafter “native HA”) mainly exists as polymers of very high molecular weight (> to 2.000 kDa) able even to reach 4.000 kDa with a chain of 10.000 disaccharides (Hascall V. C. and al., GlycoForum/Hyaluronan Today (1997), chapter 1).
  • fragmented HA has a different behavior from the native HA, and that according to the size of fragments, in other words their molecular weight, it is observed different biological effects, and even opposite (Noble P. W., Matrix Biol. (2002), vol. 21, pp. 25-29; Asari A., GlycoForum/Hyaluronan Today (2005), chapter 29 and quoted references).
  • HA fragments said of high molecular weight an effect on regeneration and healing, an important role as regulator of the inflammatory process, but also an immunosuppressive effect.
  • oligomers said of low weight are presented as entities able to activate the immune cells and to deliver endogenous signals with respect to stress, but also to be powerful inducers of inflammation and angiogenesis (Stern R., Clin. Dermatol. (2008), vol. 26, pp. 106-122; Krasinski R. et al., Postepy Hig. Med. Dosw (2007), vol. 61, pp. 683-689).
  • FIG. 1 illustrates an agarose gel.
  • the gel displays, for the three times of sampling and reaction (5 min, 15 min and 30 min), a more important distribution of HA with a high molecular weight for the MSH complex according to the invention, compared to fragmented HA non combined.
  • the technical problem that intends to solve the invention is to develop a new active ingredient based on hyaluronic acid fragments, with the double purpose:
  • the applicant's choice settled on a molecular entity under the form of a complex, combining an organic silicon derivative with hyaluronic acid calibrated fragments of molecular weight between 150 and 750 kDa, this for both following reasons.
  • the invention has for object a complex based on an organic silicon derivative characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight between 150 and 750 kDa.
  • the molecular weight of these fragments is between 150 and 600 kDa, in a way even more preferred between 250 and 600 kDa.
  • organic silicon derivative it is meant a compound defined by the following general formula (I):
  • the organic silicon derivatives according to the invention are under the form of monomers, dimers or trimers, mainly monomers or dimers, or a mixture of monomers, dimers and trimers, mainly a mixture of monomers and dimers, with a state in solution which can be represented by the following formula (II):
  • T0, T1 and T2 have respectively the formulas:
  • R is such as above defined for compounds (I), X represents a hydroxyl group or a radical R such as above defined, and r, s and t are such as that 1 ⁇ r+s+t ⁇ 3.
  • C 1 -C 4 alkyl group a hydrocarbon chain having from 1 to 4 atoms of carbon, linear, ramified, or even cyclic.
  • a group is notably a methyl, ethyl, propyl, butyl, 1-methylethyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl and cyclopropylmethyl group.
  • fragments of hyaluronic acid it is meant fragments resulting from native HA as such or from one of any of its salts, especially from sodium hyaluronate fragments.
  • the organic silicon derivative of formula (I) is chosen among the monomethylsilanetriol or the dimethylsilanediol. It is especially chosen the monomethylsilanetriol, and even more particularly the monomethylsilanetriol combined with one or several hyaluronic acid fragments of molecular weight between 150 and 600 kDa (hereafter “MSH” complex) or between 250 and 600 kDa.
  • MSH hyaluronic acid fragments of molecular weight between 150 and 600 kDa
  • the present invention also spreads to a cosmetic composition for topical application including, in association with any physiologically compatible excipient with skin, as main active ingredient, the complex such as previously defined, particularly the monomethylsilanetriol, and even more particularly the monomethylsilanetriol combined with one or several hyaluronic acid fragments of molecular weight between 150 and 600 kDa or between 250 and 600 kDa, said composition being intended for preventing or repairing the cutaneous damages related to aging for which it is necessary to boost the epidermal cell activity while limiting the catabolic action of the cutaneous tissue.
  • the complex such as previously defined, particularly the monomethylsilanetriol, and even more particularly the monomethylsilanetriol combined with one or several hyaluronic acid fragments of molecular weight between 150 and 600 kDa or between 250 and 600 kDa
  • the quantity of complex of formula (I) in the above composition is between 1 and 10% in weight in relation to the total weight of the composition, preferably between 2 and 5% in weight.
  • physiologically compatible excipient with skin a tensioactive, a preservative, body fat, a dye, an emulsifier, a gelling agent, an emollient, a moisturizer, a pigment, an antioxidant or all other adjuvant usually used in cosmetics.
  • compositions according to the invention are adapted to an administration through cutaneous topical way, presented under all forms usually used for such an administration.
  • they are formulated for instance under the form of cream, milk, gel, lotion, emulsion, etc.
  • the invention also concerns the use of a complex such as previously defined as a cytostimulating agent intended for boosting the epidermal cell (keratinocytes) activity while limiting the catabolic action of the cutaneous tissue.
  • a complex such as previously defined as a cytostimulating agent intended for boosting the epidermal cell (keratinocytes) activity while limiting the catabolic action of the cutaneous tissue.
  • a complex such as previously defined as a cytostimulating agent intended for boosting the epidermal cell (keratinocytes) activity while limiting the catabolic action of the cutaneous tissue.
  • a complex such as previously defined as a cytostimulating agent intended for boosting the epidermal cell (keratinocytes) activity while limiting the catabolic action of the cutaneous tissue.
  • the monomethylsilanetriol and even more particularly the monomethylsilanetriol combined with one or several hyaluronic acid fragments of molecular weight between 150 and 600 kDa or between 250 and
  • the present invention concerns a cosmetic care process intended for preventing or repairing cutaneous damages related to aging and for which it is necessary to boost the epidermal cell activity.
  • the process is achieved by applying on skin the composition such as previously defined, particularly based on the monomethylsilanetriol and even more particularly based on the monomethylsilanetriol combined with one or several hyaluronic acid fragments of molecular weight between 150 and 600 kDa or between 250 and 600 kDa.
  • Formula B (gel) Complex (dimethylsilanediol/HA 5% fragments 250-600 kDa) Carbomer (acrylate copolymer/acrylamide 1.5% & mineral oil) Sodium benzoate 0.2% Sorbic acid 1% 1,3-butanediol 10% Glycerine 5% Sodium carbonate 0.13% Phenoxyethanol 0.9% Water qsp 100%
  • test 4 the invention is hereafter illustrated by the following tests above described in the specification (tests 1 to 3), and a comparative study (test 4).
  • tests 1, 2 and 4 the experimental studies have been carried out on a reconstructed human epidermis model (RHE, supplier: SkinEthic®) whose interest is a strong homology with human epidermis.
  • RHE human epidermis model
  • Test 1 Evidence of the Cytostimulating Effect of the MSH Complex on Reconstructed Epidermis with Human Origin.
  • the culture of RHE consisted in placing them in a “MCDB 153 ” growth medium (supplier: SkinEthic®) containing 5 mg/mL of insulin, 1.5 mM of CaCl 2 and 25 mg/ml of gentamycine, for 24 hours at 37° C. and 5% CO 2 .
  • the culture of RHE is identical to the one of the herebefore test 1.
  • the dosage of the IL1 and IL8 pro-inflammatory interleukines is achieved on a supernatant resulting from culture medium after 24 hours of treatment, with the help of ELISA dosage kits (R&D System Quantikine Immunoassay, D800C, DTA00C and DLA50), and for identical configurations to those of the above test 1.
  • Test 3 Evidence of a Slowed Down Catabolism on Agarose Gel for the MSH Complex
  • the experimental study consisted in measuring the deterioration kinetic of the MSH complex according to the invention submitted in vitro to bovine hyaluronidases, by electrophoresis on agarose gel. 10 l of 1 mg/ml hyaluronidases are mixed to 50 l of complex in a PBS buffer solution during 30 minutes at 37° C.
  • the electrophoresis displays, for the three times of sampling and reaction, a more important distribution of HA with a high molecular weight for the MSH complex according to the invention, compared to fragmented HA non combined.
  • Test 4 Comparison of Cytostimulant Effects of the MSH Complex and of the Dimethylsilanediol Hyaluronate of High Molecular Weight

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I):

RXSi(OH)4-x  (I)
    • wherein:
      • R is a (C1-C4)alkyl, x=1 and 2.
The invention also concerns the use of such a complex in the prevention or the repair of cutaneous damages.

Description

  • This application claims priority under 35 U.S.C. 119 to French application No. FR08/05479 filed Oct. 3, 2008, which is incorporated by reference herein as if fully set forth.
  • The invention concerns a complex combining an organic silicon derivative with one or several hyaluronic acid calibrated fragments, and its use in the prevention or the repair of cutaneous damages.
  • BACKGROUND
  • Linear polysaccharide constituted of repetitive units of D-glucuronic acid and N-acetyl-D-glucosamine, the hyaluronic acid is found in the extra-cellular matrix of numerous connective tissues (skin, tendons, muscles, etc), more precisely as a polyanion called “hyaluronane”.
  • In the skin for instance, the hyaluronic acid (hereafter “HA”) is one of the major components. An important amount is indeed found in the dermal and epidermal extra-cellular matrix. Its hydrophilic and viscoelastic properties make it an essential actor in the preservation of moisturizing, volume and cutaneous cohesion.
  • The HA synthesized by fibroblasts and keratinocytes (hereafter “native HA”) mainly exists as polymers of very high molecular weight (> to 2.000 kDa) able even to reach 4.000 kDa with a chain of 10.000 disaccharides (Hascall V. C. and al., GlycoForum/Hyaluronan Today (1997), chapter 1).
  • However, the native HA is submitted in skin to a set of physiological damage reactions, notably enzymatic, called catabolism that aims at reducing it in smaller fragments (hereafter “fragmented HA”). Since several years, research teams turned their attention towards the catabolism of HA and its consequences in the organism. And the conclusion of all these works is in general unanimous, that is to say that the fragmented HA has a different behavior from the native HA, and that according to the size of fragments, in other words their molecular weight, it is observed different biological effects, and even opposite (Noble P. W., Matrix Biol. (2002), vol. 21, pp. 25-29; Asari A., GlycoForum/Hyaluronan Today (2005), chapter 29 and quoted references).
  • It is thus reported for HA fragments said of high molecular weight an effect on regeneration and healing, an important role as regulator of the inflammatory process, but also an immunosuppressive effect. On the other hand, oligomers said of low weight are presented as entities able to activate the immune cells and to deliver endogenous signals with respect to stress, but also to be powerful inducers of inflammation and angiogenesis (Stern R., Clin. Dermatol. (2008), vol. 26, pp. 106-122; Krasinski R. et al., Postepy Hig. Med. Dosw (2007), vol. 61, pp. 683-689).
  • More precisely concerning skin, it is reported a stimulation of the keratinocytes' proliferation in culture, for fragments called “of intermediate size” with a molecular weight between 50 and 400 kDa (Kaya G. and al., PLoS Medicine (2006), vol. 3, pp. 2291-2303). These effects are also observed after topical application of a preparation based on HA fragments of molecular weight between 50 and 750 kDa (described “of low molecular weight” in the specification of FR 2865651 application). This advantageous property, notably synonymous of a better barrier function of the skin with a thickness of the epidermis increased, would be however not anymore observed with small HA fragments lower than 50 kDa (Kaya G. and al., PLoS Medicine (2006), vol. 3, pp. 2291-2303).
  • Although it has been considered for a long time that a transcutaneous crossing of HA, for a benefit beyond the simple surface of the skin and the cornea layer, could be only considered for fragments of HA with very low molecular weight (< to 50 kDa, Tammi R. and al., J. Invest. Dermatol. (1991), vol. 97, pp. 126-130), it is henceforth mentioned a diffusion capacity in the epidermis for HA fragments of definitely higher size, namely for fragments from 360 to 400 kDa (Brown T. J. and al., J. Invest. Dermatol. (1999), vol. 113, pp. 740-746) or else for the above mentioned intermediate fragments (50-400 kDa). This diffusion would even go as far as able to reach the dermis with also the above referred topical preparation based on HA (50-750 kDa).
  • In the cosmetic area and especially the one combating cutaneous aging, it can be advisable to bring topically to the skin some fragmented hyaluronic acid with appropriate size, and this, in order to fight against aging effects or extrinsic factors (free radicals, ultra-violet radiation, pollution, etc). It is indeed admitted that aging or ultra-violet radiations influence the HA catabolism and the release of fragments, and can result in a lower intracellular production and a more uneven layout (Meyer and al., J. Invest. Dermatol. (1994), vol. 3, pp. 385-389). However, a cosmetic application would not satisfy with unwanted secondary effects, such as here-above mentioned pro-inflammatory effect for small fragments of hyaluronic acid.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates an agarose gel. The gel displays, for the three times of sampling and reaction (5 min, 15 min and 30 min), a more important distribution of HA with a high molecular weight for the MSH complex according to the invention, compared to fragmented HA non combined. Lane 1 represents HA fragments of molecular weight between 150-600 kDa; lane 2 represents HA fragments of molecular weight <20 kDa; lane 3 represents HA fragments of molecular weight between 150-600 kDa+enzyme (0 min: reaction time); lane 4 represents MSH complex+enzyme (0 min: reaction time); lane 5 represents HA fragments of molecular weight between 150-600 kDa+enzyme (5 min: reaction time); lane 6 represents MSH complex+enzyme (5 min: reaction time); lane 7 represents HA fragments of molecular weight between 150-600 kDa+enzyme (15 min: reaction time); lane 8 represents MSH complex+enzyme (15 min: reaction time); lane 9 represents HA fragments of molecular weight between 150-600 kDa+enzyme (30 min: reaction time); and lane 10 represents MSH complex+enzyme (30 min: reaction time)
  • DETAILED DESCRIPTION
  • Therefore in the light of what precedes conjugated to the need of new products with the comfort of a topical application, the technical problem that intends to solve the invention is to develop a new active ingredient based on hyaluronic acid fragments, with the double purpose:
      • to potentiate/increase the recognized biological effects to the hyaluronic acid fragments said of weak or medium molecular weight,
      • to avoid the pro-inflammatory adverse effect of small fragments produced by the catabolic action of cutaneous tissues.
  • The applicant's choice settled on a molecular entity under the form of a complex, combining an organic silicon derivative with hyaluronic acid calibrated fragments of molecular weight between 150 and 750 kDa, this for both following reasons.
  • Firstly, the aforesaid complex represented an advantageous reply to previously expressed purposes, illustrated by:
      • the evidence of a greatly superior cytostimulant effect on a reconstructed human epidermis model compared to the one observed for the same fragments of hyaluronic acid but not combined [see hereafter test 1], thus suggesting an effect of synergy between siliconed and hyaluronic parts of the complex.
      • a real tolerance coming with this cellular renewal since it is not observed a significant induction of pro-inflammatory cytokines compared with the used control [see hereafter test 2]. This induction is even lowered for one of the tested cytokines.
  • Secondly, unexpectedly for the applicant, it has been observed during an in vitro study on the kinetic deterioration of HA fragments with hyaluronidases a lesser sensitivity and accessibility of these HA fragments to these enzymes as soon as these fragments happen to be combined as a complex with an organic silicon derivative [see hereafter test 3]. Indeed, in comparison with fragmented HA with same weight but not combined, an agarose gel electrophoresis evidenced the presence of a more important distribution of HA fragments with high molecular weight. Such a behavior is appreciable in the context of the invention, because it is the proof of a slowed down catabolism, also suggesting a protective role of the organic silicon derivative on HA fragments as a complex.
  • In the prior art, it is nevertheless to note a cosmetic product with RnSi(OR′)m(OR″)p as formula combining an organo-silicon compound with a biologically active compound (R′), notably hyaluronic acid quoted as a non limitative instance, and a dermatophilic molecule (R″) whose role is to prevent the crossing of organic silicon in the subjacent tissues of skin (EP 0289366 patent). The R and R′ radicals are however with large scope chosen among simple organic compounds with of one or several alcohol, phenol, acid, amino or amino-acid functions. In addition in this document and even if the hyaluronic acid is listed, it is not mentioned the use of HA fragments with calibrated size, nor a particular efficiency on the epidermal cellular renewal as observed with the present invention. The same remarks apply to organo-silicon compounds under solid form within EP 0867445 european patent application, as well as for the moisturizing product object of FR 2561915 application. In this French reference, it is proposed the combination of a silanol with a hydrosoluble substance clearly under the state of polymer, such as proteins, mucopolysaccharides, notably hyaluronic acid, or else cellulose derivatives, and this for the sole effect of humidity preservation and of sticky sensation absence on skin.
  • Thus, according to a first aspect, the invention has for object a complex based on an organic silicon derivative characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight between 150 and 750 kDa.
  • According to a preferred embodiment of the invention, the molecular weight of these fragments is between 150 and 600 kDa, in a way even more preferred between 250 and 600 kDa.
  • By “organic silicon derivative”, it is meant a compound defined by the following general formula (I):

  • RXSi(OH)4-x  (I)
  • wherein:
      • R is a (C1-C4)alkyl,
      • x=1 and 2.
  • The organic silicon derivatives according to the invention are under the form of monomers, dimers or trimers, mainly monomers or dimers, or a mixture of monomers, dimers and trimers, mainly a mixture of monomers and dimers, with a state in solution which can be represented by the following formula (II):

  • [(T0)R+(T1)S+(T2)T]  (II)
  • in which:
  • T0, T1 and T2 have respectively the formulas:
  • Figure US20100113385A1-20100506-C00001
  • wherein:
  • R is such as above defined for compounds (I),
    X represents a hydroxyl group or a radical R such as above defined, and
    r, s and t are such as that 1≦r+s+t≦3.
  • In the above formulas (I) and (II), it is meant by “C1-C4 alkyl group” a hydrocarbon chain having from 1 to 4 atoms of carbon, linear, ramified, or even cyclic. Such a group is notably a methyl, ethyl, propyl, butyl, 1-methylethyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl and cyclopropylmethyl group.
  • By “fragments of hyaluronic acid”, it is meant fragments resulting from native HA as such or from one of any of its salts, especially from sodium hyaluronate fragments.
  • According to an other advantageous embodiment of the invention, the organic silicon derivative of formula (I) is chosen among the monomethylsilanetriol or the dimethylsilanediol. It is especially chosen the monomethylsilanetriol, and even more particularly the monomethylsilanetriol combined with one or several hyaluronic acid fragments of molecular weight between 150 and 600 kDa (hereafter “MSH” complex) or between 250 and 600 kDa.
  • According to another aspect, the present invention also spreads to a cosmetic composition for topical application including, in association with any physiologically compatible excipient with skin, as main active ingredient, the complex such as previously defined, particularly the monomethylsilanetriol, and even more particularly the monomethylsilanetriol combined with one or several hyaluronic acid fragments of molecular weight between 150 and 600 kDa or between 250 and 600 kDa, said composition being intended for preventing or repairing the cutaneous damages related to aging for which it is necessary to boost the epidermal cell activity while limiting the catabolic action of the cutaneous tissue.
  • Advantageously, the quantity of complex of formula (I) in the above composition is between 1 and 10% in weight in relation to the total weight of the composition, preferably between 2 and 5% in weight.
  • One can mention, as an example of physiologically compatible excipient with skin, a tensioactive, a preservative, body fat, a dye, an emulsifier, a gelling agent, an emollient, a moisturizer, a pigment, an antioxidant or all other adjuvant usually used in cosmetics.
  • The compositions according to the invention are adapted to an administration through cutaneous topical way, presented under all forms usually used for such an administration. Advantageously, they are formulated for instance under the form of cream, milk, gel, lotion, emulsion, etc.
  • According to another aspect, the invention also concerns the use of a complex such as previously defined as a cytostimulating agent intended for boosting the epidermal cell (keratinocytes) activity while limiting the catabolic action of the cutaneous tissue. It is particularly used the monomethylsilanetriol, and even more particularly the monomethylsilanetriol combined with one or several hyaluronic acid fragments of molecular weight between 150 and 600 kDa or between 250 and 600 kDa.
  • Finally, according to a last aspect, the present invention concerns a cosmetic care process intended for preventing or repairing cutaneous damages related to aging and for which it is necessary to boost the epidermal cell activity. The process is achieved by applying on skin the composition such as previously defined, particularly based on the monomethylsilanetriol and even more particularly based on the monomethylsilanetriol combined with one or several hyaluronic acid fragments of molecular weight between 150 and 600 kDa or between 250 and 600 kDa.
  • As an illustration, it is hereafter mentioned two formulation examples of cosmetic composition according to the invention, successively with the monomethylsilanetriol combined with hyaluronic acid fragments of molecular weight between 150 and 600 kDa (formula A), and with the dimethylsilanediol combined with hyaluronic acid fragments of molecular weight between 250 and 600 kDa (formula B):
  • Formula A (cream)
    MSH complex (monomethylsilanetriol/HA 5%
    fragments 150-600 kDa)
    Hydrogenated polyisobutene 7%
    Isobutyl myristate 3%
    Cetyl Palmitate
    7%
    Ethylene glycol monostearate 5%
    Sorbitan laurate 2%
    Polysorbate 20 2%
    Carbomer (acrylate copolymer/acrylamide 0.3%
    & mineral oil)
    Phenoxyethanol 0.5%
    Water qsp 100%
  • Formula B (gel)
    Complex (dimethylsilanediol/HA 5%
    fragments 250-600 kDa)
    Carbomer (acrylate copolymer/acrylamide 1.5%
    & mineral oil)
    Sodium benzoate 0.2%
    Sorbic acid
    1%
    1,3-butanediol 10%
    Glycerine
    5%
    Sodium carbonate 0.13%
    Phenoxyethanol 0.9%
    Water qsp 100%
  • As purely an indication, the invention is hereafter illustrated by the following tests above described in the specification (tests 1 to 3), and a comparative study (test 4). In tests 1, 2 and 4, the experimental studies have been carried out on a reconstructed human epidermis model (RHE, supplier: SkinEthic®) whose interest is a strong homology with human epidermis.
  • Test 1: Evidence of the Cytostimulating Effect of the MSH Complex on Reconstructed Epidermis with Human Origin.
  • The culture of RHE consisted in placing them in a “MCDB 153” growth medium (supplier: SkinEthic®) containing 5 mg/mL of insulin, 1.5 mM of CaCl2 and 25 mg/ml of gentamycine, for 24 hours at 37° C. and 5% CO2.
  • The observation of cellular proliferation is achieved with the immunotracking technique (Gerdes and al., Int. J. Cancer (1983), vol. 31, pp. 13-20) by using the “Ki67” cell proliferation tracer, for the three following configurations (after a 100 l twice-daily deposit on RHE):
  • case 1: PBS buffer solution (control)
  • case 2: HA fragments 150-600 kDa ( concentrations 2 and 5%)
  • case 3: MSH complex ( concentrations 2 and 5%)
  • The obtained results are gathered in the hereafter table 1:
  • TABLE 1
    concen- % cells expressing Ki67/
    tration number of total cells
    (%) (% in relation to the control)
    case 1 (control)
    case 2 (HAF 150-600 kDa) 2.5 0
    case 2 (HAF 150-600 kDa) 5 +28 (±0.6)
    case 3 (MSH complex) 2.5 +14 (±1.0)
    case 3 (MSH complex) 5 +63 (±0.5)
  • The results, taking values obtained from three independent experiments, underline a potentiated cytostimulation for the MSH complex according to the invention, because it is much higher to the one observed for the non combined fragmented HA.
  • Test 2: Evidence of the Absence of Pro-Inflammatory Reply Induction for the MSH Complex
  • The culture of RHE is identical to the one of the herebefore test 1. The dosage of the IL1 and IL8 pro-inflammatory interleukines is achieved on a supernatant resulting from culture medium after 24 hours of treatment, with the help of ELISA dosage kits (R&D System Quantikine Immunoassay, D800C, DTA00C and DLA50), and for identical configurations to those of the above test 1.
  • The obtained results are gathered in the hereafter table 2:
  • TABLE 2
    concen-
    tration IL1α quantity IL8 quantity
    (%) (pg/ml) (pg/ml)
    case 1 (control) 1.8 (±0.1)  38.8 (±11.5)
    case 2 (HAF 150-600 kDa) 2.5 1.4 (±0)   40.2 (±4.9)
    case 2 (HAF 150-600 kDa) 5 0.6 (±0.3) 31.0 (±0.6)
    case 3 (MSH complex) 2.5 3.5 (±1.8) 20.1 (±7.2)
    case 3 (MSH complex) 5 3.4 (±0.8)  34.8 (±13.7)
  • No significant induction of pro-inflammatory cytokines is observed for the MSH complex according to the invention. It is even observed, in relation to the control as well as in relation to the non combined HA fragment, a reduction of the IL8 type-interleukines' rate.
  • Test 3: Evidence of a Slowed Down Catabolism on Agarose Gel for the MSH Complex
  • The experimental study consisted in measuring the deterioration kinetic of the MSH complex according to the invention submitted in vitro to bovine hyaluronidases, by electrophoresis on agarose gel. 10 l of 1 mg/ml hyaluronidases are mixed to 50 l of complex in a PBS buffer solution during 30 minutes at 37° C.
  • Successively at 5, 15 and 30 minutes, 10 l of reaction mixture are taken, then heated at 95° C. in order to stop the enzymatic reaction. These 10 l are then deposited on an agarose gel and a suitable stain (Stains All®) is used for the electrophoresis disclosure.
  • As the agarose gel represented on the hereafter FIG. 1, the electrophoresis displays, for the three times of sampling and reaction, a more important distribution of HA with a high molecular weight for the MSH complex according to the invention, compared to fragmented HA non combined.
  • Test 4: Comparison of Cytostimulant Effects of the MSH Complex and of the Dimethylsilanediol Hyaluronate of High Molecular Weight
  • Identically to the here-above test 1, keratinocytes' cellular proliferation is observed on reconstructed human epidermis RHE (with the immunotracking technique) for:
      • the MSH complex according to the invention (based on 150-600 kDa HA fragments)
      • the dimethylsilanediol hyaluronate marketed by the applicant under the “D.S.H. CN®” brand mark.
      • D.S.H. CN® is an organo-silicon product resulting from the combination of dimethylsilanediol with hyaluronic acid of high molecular weight (1500 to 2200 kDa HA fragments).
  • The obtained results are gathered in the hereafter table 4, again in relation to a PBS buffer solution (control):
  • TABLE 4
    concen- % cells expressing Ki67/
    tration number of total cells
    (%) (% in relation to the control)
    control
    D.S.H. CN ® 5    0 (±2.2)
    MSH complex 5 +69.5 (±3.1)

Claims (11)

1. A complex based on an organic silicon derivative wherein said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight between 150 and 750 kDa, said derivative being of general formula (I):

RXSi(OH)4-x  (I)
wherein:
R is a (C1-C4)alkyl,
x=1 and 2.
2. The complex according to claim 1, wherein the molecular weight of said fragments are between 150 and 600 kDa.
3. The complex according to claim 1, wherein the molecular weight of said fragments are between 250 and 600 kDa.
4. The complex according to claim 1, wherein said organic silicon derivative of formula (I) is chosen among the monomethylsilanetriol or the dimethylsilanediol.
5. The complex according to claim 4, wherein the organic silicon derivative is the monomethylsilanetriol.
6. The complex according to claim 1, wherein the monomethylsilanetriol is combined with one or several hyaluronic acid fragments of molecular weight between 150 and 600 kDa or between 250 and 600 kDa.
7. A cosmetic composition for topical application intended for preventing or repairing cutaneous damages related to aging wherein it includes, in association with any physiologically compatible excipient with skin, as main active ingredient, a complex according to claim 1.
8. The cosmetic composition according to claim 7, wherein the quantity of complex of formula (I) is between 1 and 10% in weight in relation to the total weight of the composition, preferably between 2 and 5% in weight.
9. The cosmetic composition according to claim 7, wherein it is formulated under the form of cream, milk, gel, lotion, emulsion.
10. A cosmetic care process intended for preventing or repairing cutaneous damages related to aging, the process achieved by applying on skin a composition such as defined in claim 7.
11. A process intended for boosting the epidermal cell activity and limiting the catabolic action of the cutaneous tissue comprising administering a complex such as defined to claim 1 as a cytostimulating agent.
US12/572,658 2008-10-03 2009-10-02 Complex combining an organic silicon derivative with hyaluronic acid calibrated fragments, for preventive and repairing action of cutaneous damages Abandoned US20100113385A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/649,640 US8822433B2 (en) 2008-10-03 2012-10-11 Complex combining an organic silicon derivative with hyaluronic and acid calibrated fragments, for preventive and repairing action of cutaneous damages

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRFR08/05479 2008-10-03
FR0805479A FR2936708B1 (en) 2008-10-03 2008-10-03 COMPLEX COMPRISING AN ORGANIC DERIVATIVE OF SILICON WITH CALIBER FRAGMENTS OF HYALURONIC ACID, WITH PREVENTIVE ACTION AND REPAIR OF SKIN DEGRADATION.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/649,640 Division US8822433B2 (en) 2008-10-03 2012-10-11 Complex combining an organic silicon derivative with hyaluronic and acid calibrated fragments, for preventive and repairing action of cutaneous damages

Publications (1)

Publication Number Publication Date
US20100113385A1 true US20100113385A1 (en) 2010-05-06

Family

ID=40677691

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/572,658 Abandoned US20100113385A1 (en) 2008-10-03 2009-10-02 Complex combining an organic silicon derivative with hyaluronic acid calibrated fragments, for preventive and repairing action of cutaneous damages
US13/649,640 Active US8822433B2 (en) 2008-10-03 2012-10-11 Complex combining an organic silicon derivative with hyaluronic and acid calibrated fragments, for preventive and repairing action of cutaneous damages

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/649,640 Active US8822433B2 (en) 2008-10-03 2012-10-11 Complex combining an organic silicon derivative with hyaluronic and acid calibrated fragments, for preventive and repairing action of cutaneous damages

Country Status (7)

Country Link
US (2) US20100113385A1 (en)
EP (1) EP2172186B1 (en)
ES (1) ES2615360T3 (en)
FR (1) FR2936708B1 (en)
PL (1) PL2172186T3 (en)
PT (1) PT2172186T (en)
SI (1) SI2172186T1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230181444A1 (en) * 2020-05-20 2023-06-15 Exsymol Sam Compositions comprising organo-silanol compounds, and applications

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3051672B1 (en) * 2016-05-30 2020-04-24 Exsymol COSMETIC OR DERMOCOSMETIC COMPOSITION COMPRISING A SUREAU EXTRACT AND AN ORGANIC SILICON DERIVATIVE
BE1026018B1 (en) * 2018-02-19 2019-09-16 Soles Mundi Sprl Composition comprising monomethylsilanetriol
FR3094211B1 (en) * 2019-04-01 2023-11-17 Exsymol Sa cosmetic use of organosilicon compounds
EP4385486A1 (en) 2022-12-16 2024-06-19 Laboratoires Fill-Med Manufacturing Combination of an organosilicon compound with a crosslinked glycosaminoglucan for preventing and repairing cutaneous ageing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037803A (en) * 1987-03-04 1991-08-06 Jean Gueyne Product comprising a silicon organic compound combined with a cosmetically active substance
US20070172442A1 (en) * 2004-01-29 2007-07-26 Pierre Fabre Dermo-Cosmetique Topical compositions associating sodium hyaluronate fragments and retinoid useful for cosmetic and medical dermatology

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60204708A (en) 1984-03-30 1985-10-16 Lion Corp Humectant
FR2761074B1 (en) 1997-03-24 1999-05-28 Exsymol Sa BIOLOGICALLY ACTIVE SILICON COMPOUNDS IN SOLID FORM
FR2865935B1 (en) 2004-02-05 2006-06-23 Exsymol Sa USE OF ORGANO-SILICY COMPOUNDS FOR CONSTRAINTING CONNECTIVE TISSUES FOUNDED THROUGH MECHANICAL ACTION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037803A (en) * 1987-03-04 1991-08-06 Jean Gueyne Product comprising a silicon organic compound combined with a cosmetically active substance
US20070172442A1 (en) * 2004-01-29 2007-07-26 Pierre Fabre Dermo-Cosmetique Topical compositions associating sodium hyaluronate fragments and retinoid useful for cosmetic and medical dermatology

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Brown., Chem. Soc. Rev., 1978,7, 359-376. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230181444A1 (en) * 2020-05-20 2023-06-15 Exsymol Sam Compositions comprising organo-silanol compounds, and applications

Also Published As

Publication number Publication date
EP2172186A1 (en) 2010-04-07
US8822433B2 (en) 2014-09-02
FR2936708B1 (en) 2012-08-17
PT2172186T (en) 2017-02-08
US20130035308A1 (en) 2013-02-07
SI2172186T1 (en) 2017-04-26
FR2936708A1 (en) 2010-04-09
PL2172186T3 (en) 2017-06-30
EP2172186B1 (en) 2016-11-30
ES2615360T3 (en) 2017-06-06

Similar Documents

Publication Publication Date Title
KR101715631B1 (en) Compositions and methods for skin care
US8496917B2 (en) Compositions and methods for improving skin appearance
US8822433B2 (en) Complex combining an organic silicon derivative with hyaluronic and acid calibrated fragments, for preventive and repairing action of cutaneous damages
US6172250B1 (en) Preparation process of biologically active silicon compounds in a concentrated form
US9115176B2 (en) Compounds, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same
ES2507495T3 (en) Use of heparan sulfate in cosmetological and dermatological preparations
EP3120831A1 (en) Topical delivery of skin compositions having low ph
US20130183257A1 (en) Compositions and methods for improving skin appearance
US10279076B2 (en) Composition for maintaining efficacy of filler
CN115024997B (en) Cosmetic composition with skin aging resisting effect
AU2009256524B2 (en) Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
US10653615B2 (en) Use of a photosynthetic cell extract comprising functional thylakoids in cosmetic compositions
CN101712728B (en) A compound by combining organosilicon derivates and corrective hyaluronic acid fragments
WO2015141978A1 (en) Composition for maintaining efficacy of filler
KR102215170B1 (en) Composition for moisturizing the skin containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester
CN115381803A (en) Retinoid compositions and uses thereof
KR20110030182A (en) Anti-wrinkle composition
KR20030024322A (en) Cosmetic composition containing adenosine-3&#39;,5&#39;-cyclic monophosphoric acid as a skin elasticity improving agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: EXSYMOL S.A.M.,MONACO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SEGUIN, MARIE CHRISTINE;REEL/FRAME:024408/0826

Effective date: 20100511

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION